JP2014516552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516552A5 JP2014516552A5 JP2014513800A JP2014513800A JP2014516552A5 JP 2014516552 A5 JP2014516552 A5 JP 2014516552A5 JP 2014513800 A JP2014513800 A JP 2014513800A JP 2014513800 A JP2014513800 A JP 2014513800A JP 2014516552 A5 JP2014516552 A5 JP 2014516552A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- cancer
- biomarkers
- biomarker
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161492488P | 2011-06-02 | 2011-06-02 | |
| US61/492,488 | 2011-06-02 | ||
| PCT/US2012/040805 WO2012167278A1 (en) | 2011-06-02 | 2012-06-04 | Molecular diagnostic test for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248061A Division JP2017079772A (ja) | 2011-06-02 | 2016-12-21 | 癌の分子的診断検査 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516552A JP2014516552A (ja) | 2014-07-17 |
| JP2014516552A5 true JP2014516552A5 (enExample) | 2016-02-25 |
| JP6067686B2 JP6067686B2 (ja) | 2017-01-25 |
Family
ID=47259970
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513800A Expired - Fee Related JP6067686B2 (ja) | 2011-06-02 | 2012-06-04 | 癌の分子的診断検査 |
| JP2016248061A Withdrawn JP2017079772A (ja) | 2011-06-02 | 2016-12-21 | 癌の分子的診断検査 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016248061A Withdrawn JP2017079772A (ja) | 2011-06-02 | 2016-12-21 | 癌の分子的診断検査 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10260097B2 (enExample) |
| EP (1) | EP2715348B1 (enExample) |
| JP (2) | JP6067686B2 (enExample) |
| KR (1) | KR20140044341A (enExample) |
| CN (1) | CN103733065B (enExample) |
| AU (1) | AU2012261820B2 (enExample) |
| BR (1) | BR112013031019A2 (enExample) |
| CA (1) | CA2838086A1 (enExample) |
| EA (2) | EA025926B1 (enExample) |
| IL (1) | IL229681A0 (enExample) |
| MX (1) | MX2013014065A (enExample) |
| SG (2) | SG195208A1 (enExample) |
| WO (1) | WO2012167278A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA025926B1 (ru) | 2011-06-02 | 2017-02-28 | Олмак Дайэгностикс Лимитед | Молекулярно-диагностический тест на рак |
| EP2667193A1 (en) * | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| WO2014055398A1 (en) | 2012-10-05 | 2014-04-10 | Siemens Healthcare Diagnostics Inc. | Method for detecting an increased risk or incidence of colorectal cancer |
| AU2013353839A1 (en) * | 2012-12-03 | 2015-06-18 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| GB201313342D0 (en) * | 2013-07-26 | 2013-09-11 | Cancer Rec Tech Ltd | Biomarkers |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| WO2016011052A1 (en) * | 2014-07-14 | 2016-01-21 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| US20170247758A1 (en) * | 2014-08-18 | 2017-08-31 | Drexel University | Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment |
| KR20160101706A (ko) * | 2015-02-17 | 2016-08-25 | 싸이퍼롬, 인코퍼레이티드 | 자궁수축억제제 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 자궁수축억제제 선택 방법 |
| CN105160208A (zh) * | 2015-05-29 | 2015-12-16 | 杭州奥视图像技术有限公司 | 用于疾病亚型问题的基于网络的聚类方法 |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| HRP20202019T1 (hr) | 2015-07-01 | 2021-04-30 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora |
| US10650325B2 (en) * | 2015-07-31 | 2020-05-12 | Microsoft Technology Licensing, Llc | Deterministic message distribution |
| CA2996426A1 (en) | 2015-10-05 | 2017-04-13 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| ES2908848T3 (es) * | 2016-01-25 | 2022-05-04 | Sanofi Sa | Método de predicción del resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer midiendo el nivel de un biomarcador de plasma |
| US20190127805A1 (en) * | 2016-03-15 | 2019-05-02 | Almac Diagnostics Limited | Gene signatures for cancer detection and treatment |
| JP6899848B2 (ja) | 2016-12-28 | 2021-07-07 | 公益財団法人がん研究会 | 抗ｖｅｇｆｒ−２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット |
| CN107037210A (zh) * | 2017-04-05 | 2017-08-11 | 北京蛋白质组研究中心 | Thbs2蛋白检测物在制备肝细胞癌诊断试剂盒中的应用 |
| US20200200760A1 (en) * | 2017-05-16 | 2020-06-25 | Lankenau Institute Of Medical Research | Compositions comprising ligands to rhob protein and the uses thereof |
| US10311967B2 (en) | 2017-06-13 | 2019-06-04 | Bostongene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
| US20180365372A1 (en) * | 2017-06-19 | 2018-12-20 | Jungla Inc. | Systems and Methods for the Interpretation of Genetic and Genomic Variants via an Integrated Computational and Experimental Deep Mutational Learning Framework |
| EP3461916A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3461915A1 (en) | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
| WO2019165366A1 (en) * | 2018-02-23 | 2019-08-29 | Beth Israel Deaconess Medical Center | Drug efficacy evaluations |
| US11681953B2 (en) * | 2018-04-13 | 2023-06-20 | Freenome Holdings, Inc. | Machine learning implementation for multi-analyte assay development and testing |
| AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
| CA3107571A1 (en) * | 2018-06-27 | 2020-01-02 | Qcdx Llc | Biological sample holder and handler |
| CN109585011A (zh) * | 2018-10-26 | 2019-04-05 | 朱海燕 | 胸痛患者的病症诊断方法及机器可读存储介质 |
| JP2022513038A (ja) * | 2018-11-14 | 2022-02-07 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合薬を使用する癌の治療方法 |
| US20210118527A1 (en) * | 2019-07-22 | 2021-04-22 | Mission Bio, Inc. | Using Machine Learning to Optimize Assays for Single Cell Targeted DNA Sequencing |
| KR102289533B1 (ko) * | 2019-08-19 | 2021-08-17 | 주식회사 테라젠바이오 | 특정 약물의 타겟 유전자와 관련된 시그니처를 기초로 타겟 유전자와 관련된 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램 |
| US11049590B1 (en) | 2020-02-12 | 2021-06-29 | Peptilogics, Inc. | Artificial intelligence engine architecture for generating candidate drugs |
| BR112022022338A2 (pt) * | 2020-05-04 | 2023-01-10 | Amgen Inc | Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso |
| TW202208355A (zh) * | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| CN112489800B (zh) * | 2020-12-03 | 2024-05-28 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的预后评估系统及其应用 |
| CN116312814B (zh) * | 2021-12-02 | 2024-09-27 | 复旦大学 | 一种肺腺癌分子分型模型的构建方法、设备、装置以及试剂盒 |
| CN114624441B (zh) * | 2022-03-04 | 2025-07-18 | 中国人民解放军空军军医大学 | 跨膜蛋白43作为胰腺癌肿瘤诊断标志物的应用 |
| CN115902223B (zh) * | 2022-11-15 | 2025-08-26 | 中国人民解放军空军军医大学 | 蛋白生物标志物在胃癌诊断中的应用 |
| CN116863995B (zh) * | 2023-08-29 | 2024-05-14 | 北京大学第一医院 | Alpk2，itga11，esyt1，cdh17在预测药物出血中的应用 |
| CN118393140B (zh) * | 2024-04-24 | 2025-04-11 | 英科众康(厦门)科技有限公司 | 基于适配体/抗体新型夹心式介导的检测技术在泛癌标志物c1qc诊断中的应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| WO1993020236A1 (en) | 1992-04-03 | 1993-10-14 | Applied Biosystems, Inc. | Probe composition and method |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| US6946442B2 (en) | 1994-11-30 | 2005-09-20 | Asif Syed Ahmed | Method of hastening cervical ripening |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| JP2002515738A (ja) | 1996-01-23 | 2002-05-28 | アフィメトリックス，インコーポレイティド | 核酸分析法 |
| US6680175B2 (en) * | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| US6998234B2 (en) | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| WO2003096981A2 (en) | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| AU2003281325A1 (en) | 2002-07-02 | 2004-01-23 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| KR20160014775A (ko) * | 2003-05-30 | 2016-02-11 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체를 사용한 치료 |
| WO2004108896A2 (en) | 2003-06-03 | 2004-12-16 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
| EP1704250B1 (en) | 2003-12-31 | 2012-09-19 | The Penn State Research Foundation | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer |
| US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| EP1737980A2 (en) | 2004-04-09 | 2007-01-03 | Fondazione IRCCS Istituto Nazionale dei Tumori | Gene expression markers for predicting response to chemotherapy |
| EP1756306A2 (en) * | 2004-05-14 | 2007-02-28 | Ludwig Institute For Cancer Research | Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib |
| MX2007000944A (es) * | 2004-07-23 | 2007-04-13 | Astrazeneca Ab | Metodo para pronosticar la sensibilidad de un tumor a farmacos del receptor erbb. |
| US20060134663A1 (en) | 2004-11-03 | 2006-06-22 | Paul Harkin | Transcriptome microarray technology and methods of using the same |
| US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| ATE477495T1 (de) * | 2005-03-16 | 2010-08-15 | Osi Pharm Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
| WO2007015947A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
| EP1926996B1 (en) * | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| EP1963862A4 (en) * | 2005-12-05 | 2010-03-03 | Merck & Co Inc | METHOD FOR PREDICTING THE APPLICATION FOR TREATMENT BASED ON THE EXPRESSION PROFILES OF PROTEIN AND TRANSCRIPTION BIOMARKERS |
| WO2007067500A2 (en) | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| AU2007211085A1 (en) | 2006-01-27 | 2007-08-09 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
| CA2639070A1 (en) * | 2006-04-13 | 2007-11-01 | Oncomethylime Sciences S.A. | Novel tumour suppressor |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| CN101541977A (zh) | 2006-09-19 | 2009-09-23 | 诺瓦提斯公司 | 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物 |
| NZ582941A (en) | 2007-08-13 | 2012-05-25 | Almac Diagnostics Ltd | A 3' -based sequencing approach for microarray manufacture |
| WO2009042814A1 (en) | 2007-09-25 | 2009-04-02 | Minerva Biotechnologies Corp. | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| MX2010005057A (es) | 2007-11-09 | 2010-05-19 | Genentech Inc | Metodos y composiciones para uso de diagnostico en pacientes de cancer. |
| US20100279892A1 (en) | 2007-12-07 | 2010-11-04 | Mcweeney Shannon K | Methods to determine if a subject will respond to a bcr-abl inhibitor |
| US8114593B2 (en) | 2008-03-12 | 2012-02-14 | University Of Medicine And Dentistry Of New Jersey | Cancer biomarker genes and gene products and methods for using the same |
| JP2011525106A (ja) | 2008-06-04 | 2011-09-15 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ | 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法 |
| EP2294420B8 (en) | 2008-06-06 | 2015-10-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Survival predictor for diffuse large B cell lymphoma |
| AU2009270851A1 (en) * | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute, Inc. | Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| EP2706358A3 (en) | 2008-12-23 | 2014-05-07 | Merck Patent GmbH | Biomarkers for inhibitors with anti-angiogenic activity |
| WO2010088688A2 (en) * | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| SG10201401722XA (en) | 2009-05-01 | 2014-08-28 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy |
| US7615353B1 (en) * | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| JP5606537B2 (ja) * | 2009-09-17 | 2014-10-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌患者における診断使用のための方法及び組成物 |
| MY166040A (en) | 2010-09-15 | 2018-05-21 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| WO2012052757A1 (en) * | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| US20150024952A1 (en) | 2010-12-28 | 2015-01-22 | Arlet Alarcon | Molecular profiling for cancer |
| EA025926B1 (ru) | 2011-06-02 | 2017-02-28 | Олмак Дайэгностикс Лимитед | Молекулярно-диагностический тест на рак |
| BR112014017320A2 (en) | 2012-01-13 | 2018-05-29 | Genentech, Inc | method for determining whether a patient is prone to respond to treatment with a vegf antagonist, method for optimizing the therapeutic efficacy of a vegf antagonist, method for selecting a therapy, method for identifying a biomarker, and method for diagnosing an angiogenic disorder |
| EP2667193A1 (en) | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| AU2013353839A1 (en) | 2012-12-03 | 2015-06-18 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
-
2012
- 2012-06-04 EA EA201391805A patent/EA025926B1/ru not_active IP Right Cessation
- 2012-06-04 KR KR1020137034588A patent/KR20140044341A/ko not_active Ceased
- 2012-06-04 WO PCT/US2012/040805 patent/WO2012167278A1/en not_active Ceased
- 2012-06-04 CA CA2838086A patent/CA2838086A1/en not_active Abandoned
- 2012-06-04 EP EP12793609.4A patent/EP2715348B1/en active Active
- 2012-06-04 US US14/123,406 patent/US10260097B2/en not_active Expired - Fee Related
- 2012-06-04 SG SG2013088216A patent/SG195208A1/en unknown
- 2012-06-04 CN CN201280037298.2A patent/CN103733065B/zh not_active Expired - Fee Related
- 2012-06-04 EA EA201691257A patent/EA201691257A1/ru unknown
- 2012-06-04 SG SG10201604497UA patent/SG10201604497UA/en unknown
- 2012-06-04 JP JP2014513800A patent/JP6067686B2/ja not_active Expired - Fee Related
- 2012-06-04 BR BR112013031019A patent/BR112013031019A2/pt not_active IP Right Cessation
- 2012-06-04 MX MX2013014065A patent/MX2013014065A/es unknown
- 2012-06-04 AU AU2012261820A patent/AU2012261820B2/en not_active Ceased
-
2013
- 2013-11-28 IL IL229681A patent/IL229681A0/en unknown
-
2016
- 2016-12-21 JP JP2016248061A patent/JP2017079772A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516552A5 (enExample) | ||
| JP2017506506A5 (enExample) | ||
| Zhan et al. | Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis | |
| Sharma et al. | Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma | |
| JP2015536667A5 (enExample) | ||
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| MX2020001227A (es) | Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes. | |
| WO2014140933A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| BR112016018044A2 (pt) | teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer | |
| BR112016004963A2 (pt) | biomarcadores para determinação precoce de uma resposta crítica ou de risco de vida para resposta de tratamento e/ou doença | |
| Yang et al. | Expression of STIM1 is associated with tumor aggressiveness and poor prognosis in breast cancer | |
| JP2015504677A5 (enExample) | ||
| JP2012524278A5 (enExample) | ||
| MX2016004557A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| EP2596363A1 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
| MX384423B (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). | |
| Xuelei et al. | ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: A meta-analysis | |
| Saadeh et al. | Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy | |
| WO2016203262A3 (en) | Gene signatures predictive of metastatic disease | |
| Hu et al. | The prognostic nutritional index and tumor pathological characteristics predict the prognosis of elderly patients with early-stage hepatocellular carcinoma after surgery | |
| JP2017500584A5 (enExample) | ||
| Alaklabi et al. | Immunotherapy in malignant peritoneal mesothelioma | |
| MX2016009450A (es) | Ensayo novedoso para detectar periostina humana. | |
| JP2016528914A5 (enExample) |